Cantor Fitzgerald Reaffirms Neutral Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Cantor Fitzgerald reaffirmed their neutral rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research note issued to investors on Friday, Benzinga reports. They currently have a $220.00 price target on the biopharmaceutical company’s stock.

A number of other equities analysts have also recently commented on the company. Citigroup lifted their price target on Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the stock a buy rating in a research note on Friday, August 2nd. The Goldman Sachs Group upgraded shares of Alnylam Pharmaceuticals from a neutral rating to a buy rating and upped their price target for the company from $198.00 to $370.00 in a report on Friday, August 16th. Stifel Nicolaus raised their price target on shares of Alnylam Pharmaceuticals from $215.00 to $295.00 and gave the stock a buy rating in a report on Thursday, June 27th. Leerink Partners upped their price objective on shares of Alnylam Pharmaceuticals from $138.00 to $159.00 and gave the company a market perform rating in a research note on Tuesday, June 25th. Finally, Evercore ISI raised their target price on Alnylam Pharmaceuticals from $210.00 to $260.00 and gave the stock an outperform rating in a research note on Tuesday, June 25th. Six research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Alnylam Pharmaceuticals has an average rating of Moderate Buy and a consensus price target of $285.95.

Alnylam Pharmaceuticals Stock Performance

ALNY stock opened at $283.32 on Friday. Alnylam Pharmaceuticals has a one year low of $141.98 and a one year high of $287.55. The company has a market capitalization of $35.84 billion, a PE ratio of -105.72 and a beta of 0.39. The company’s 50 day moving average price is $269.46 and its two-hundred day moving average price is $213.46.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.61. The business had revenue of $659.83 million during the quarter, compared to the consensus estimate of $447.22 million. During the same period in the prior year, the firm earned ($2.21) earnings per share. The business’s revenue for the quarter was up 107.0% on a year-over-year basis. On average, research analysts predict that Alnylam Pharmaceuticals will post -2.73 EPS for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In related news, Director Dennis A. Ausiello sold 20,250 shares of the firm’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the completion of the transaction, the director now owns 136 shares of the company’s stock, valued at $35,632. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CEO Yvonne Greenstreet sold 15,000 shares of the stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the sale, the chief executive officer now owns 73,441 shares in the company, valued at $20,563,480. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Dennis A. Ausiello sold 20,250 shares of the firm’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the sale, the director now directly owns 136 shares of the company’s stock, valued at $35,632. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 50,398 shares of company stock valued at $13,595,460 in the last ninety days. 1.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Alnylam Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the business. Creative Planning boosted its position in shares of Alnylam Pharmaceuticals by 24.6% during the third quarter. Creative Planning now owns 10,012 shares of the biopharmaceutical company’s stock valued at $2,754,000 after buying an additional 1,978 shares during the last quarter. Exchange Traded Concepts LLC lifted its stake in Alnylam Pharmaceuticals by 4.0% during the 3rd quarter. Exchange Traded Concepts LLC now owns 3,568 shares of the biopharmaceutical company’s stock valued at $981,000 after acquiring an additional 136 shares during the period. Livforsakringsbolaget Skandia Omsesidigt boosted its holdings in shares of Alnylam Pharmaceuticals by 400.0% during the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 1,000 shares of the biopharmaceutical company’s stock valued at $275,000 after acquiring an additional 800 shares during the last quarter. Tobam grew its stake in shares of Alnylam Pharmaceuticals by 5.8% in the third quarter. Tobam now owns 31,467 shares of the biopharmaceutical company’s stock worth $8,654,000 after acquiring an additional 1,736 shares during the period. Finally, Perpetual Ltd purchased a new position in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $1,131,000. Institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.